A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Olodanrigan (Primary)
- Indications Diabetic neuropathies; Musculoskeletal pain; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Spinifex Pharmaceuticals
- 25 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 10 Feb 2015 According to Spinifex Pharmaceuticals media release, intended initiation date is in mid 2015.
- 14 Apr 2014 New trial record